Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Eli Lilly and Novo Nordisk dominate the weight loss market, but they focus on common forms of obesity with drugs like Wegovy and Zepbound. Rhythm Pharmaceuticals, a lesser-known biotech, targets rare forms of obesity caused by genetic disorders or brain damage. Duquesne Family Office, a firm managed by billionaire Stanley Druckenmiller, recently invested in Rhythm Pharmaceuticals' stock, signaling confidence in its potential.

Rhythm Pharmaceuticals' Imcivree is currently approved for chronic weight management in patients with specific protein deficiencies, such as POMC deficiency, which controls appetite. The company recently expanded Imcivree's approval to chronic weight management in patients with acquired hypothalamic obesity, a condition affecting around 25,000 to 28,000 patients globally.

This new indication has quadrupled Rhythm Pharmaceuticals' addressable market. The company also reported positive phase 2 results for Imcivree in patients with Prader-Willi syndrome, a rare genetic condition that leads to constant hunger and obesity. If approved, this expansion could significantly boost Rhythm Pharmaceuticals' financial results.

However, Rhythm Pharmaceuticals faces significant risks, including potential clinical and regulatory setbacks and increased competition in its niche market. As of now, the biotech only generates minor revenue but is growing rapidly. Investors should consider adding a small position in Rhythm Pharmaceuticals as it makes progress in clinical and commercial aspects.